Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 5, 2012 - Issue 6
Submit an article Journal homepage
131
Views
17
CrossRef citations to date
0
Altmetric
Drug Profile

Teriflunomide for oral therapy in multiple sclerosis

Athina Papadopoulou Department of Neurology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland; Medical Image Analysis Center, Schanzenstrasse 55, 4031 Basel, CH, Switzerland; Department of Neurology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland; Medical Image Analysis Center, Schanzenstrasse 55, 4031 Basel, CH, Switzerland
,
Ludwig Kappos Department of Neurology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland; Department of Neurology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland
&
Till Sprenger Department of Neurology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland; Division of Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital of Basel, Basel, CH, Switzerland. [email protected]; Division of Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital of Basel, Basel, CH, Switzerland. [email protected]
Pages 617-628 | Published online: 10 Jan 2014

References

  • Alldred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. 2(1), 125–137 (2001).
  • Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity–I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmacol. 7(1), 7–18 (1985).
  • Kaplan MJ. Leflunomide Aventis Pharma. Curr. Opin. Investig. Drugs 2(2), 222–230 (2001).
  • Kaltwasser JP, Nash P, Gladman D et al.; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 50(6), 1939–1950 (2004).
  • Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Semin. Immunopathol. 14(4), 381–394 (1993).
  • Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta 1286(3), 153–181 (1996).
  • Henderson JF, Paterson ARP. Nucleotide Metabolism – An Introduction. Academic Press, NY, USA (1973).
  • Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59(11), 841–849 (2000).
  • Cherwinski HM, Cohn RG, Cheung P et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275(2), 1043–1049 (1995).
  • Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol. 50(6), 861–867 (1995).
  • Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270(50), 29682–29689 (1995).
  • Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47(2–3), 273–289 (2000).
  • Rückemann K, Fairbanks LD, Carrey EA et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. 273(34), 21682–21691 (1998).
  • Kent C, Carman GM, Spence MW, Dowhan W. Regulation of eukaryotic phospholipid metabolism. FASEB J. 5(9), 2258–2266 (1991).
  • Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162(1), 1–11 (2010).
  • Hirotani M, Niino M, Sasaki H. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy. Curr. Med. Chem. 17(28), 3215–3222 (2010).
  • Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159(1), 22–27 (1997).
  • González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, Aragón-Bodi A, Díaz Sánchez B, Sánchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann. Rheum. Dis. 68(10), 1644–1650 (2009).
  • Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160(4), 1581–1588 (1998).
  • Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor b and g chains mediate the signal for T-cell proliferation. Nature 369(6478), 333–336 (1994).
  • Russell SM, Johnston JA, Noguchi M et al. Interaction of IL-2R β and γ c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266(5187), 1042–1045 (1994).
  • Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr. Opin. Oncol. 23(6), 609–616 (2011).
  • West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs 10(5), 491–504 (2009).
  • Jiang Z, Li H, Fitzgerald DC, Zhang GX, Rostami A. MOG(35–55) i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways. Eur. J. Immunol. 39(3), 789–799 (2009).
  • Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270(21), 12398–12403 (1995).
  • Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334(2), 161–164 (1993).
  • Feng H, Li XY, Zheng JR, Gao JW, Xu LF, Tang MY. Inhibition of the nuclear factor-kB signaling pathway by leflunomide or triptolide also inhibits the anthralin-induced inflammatory response but does not affect keratinocyte growth inhibition. Biol. Pharm. Bull. 28(9), 1597–1602 (2005).
  • Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-𝛋 B activation and gene expression. J. Immunol. 162(4), 2095–2102 (1999).
  • Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-𝛋 B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 165(10), 5962–5969 (2000).
  • Papadopoulou A, D’Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin. Investig. Drugs 19(12), 1603–1612 (2010).
  • Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br. J. Pharmacol. 127(7), 1589–1596 (1999).
  • Muthian G, Raikwar HP, Johnson C et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J. Clin. Immunol. 26(1), 73–85 (2006).
  • Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61(4), 635–642 (1996).
  • Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmacol. Exp. Ther. 272(1), 460–468 (1995).
  • Bartlett RR, Dimitrijevic M, Mattar T et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 32(1–2), 10–21 (1991).
  • Layseca-Espinosa E, Pedraza-Alva G, Montiel JL et al. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J. Leukoc. Biol. 74(6), 1083–1093 (2003).
  • Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide–mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 76(5), 950–960 (2004).
  • Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J. Immunol. 169(6), 3392–3399 (2002).
  • Zeyda M, Poglitsch M, Geyeregger R et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 52(9), 2730–2739 (2005).
  • Shapiro S, Galboiz Y, Lahat N, Kinarty A, Miller A. The ‘immunological-synapse’ at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β. J. Neuroimmunol. 144(1–2), 116–124 (2003).
  • Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Pt 8), 1953–1971 (2006).
  • McMonagle-Strucko K, Hanak S, Pu SF et al. Teriflunomide reduces neurological behaviour and pathology in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Mult. Scler. 15, Abstract P833, (2009).
  • Mc Monagle-Strucko K, Ji Z, Petty M et al. Effects of prophylactic teriflunomide in transcranial magnetic stimulation-induced motor evoked potentials in the DA-rat model of experimental autoimmune encephalomyelitis. Mult. Scler. 17, Abstract P541 (2011).
  • Petty M, Lee L, Ying X et al. Teriflunomide treatment reduces infiltration of macrophages, t cells and b cells and increases survival of oligodendrocytes in the spinal cord of the dakr agouti rat model of experimental allergic encephalomyelitis. Neurology 74, Abstract P05 033 (2010).
  • Limsakun T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Neurology 74, Abstract P05 032 (2010).
  • De Santis M, Straface G, Cavaliere A, Carducci B, Caruso A. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann. Rheum. Dis. 64(7), 1096–1097 (2005).
  • O’Connor PW, Li D, Freedman MS et al.; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66(6), 894–900 (2006).
  • O’Connor P, Wolinsky JS, Confavreux C et al.; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365(14), 1293–1303 (2011).
  • Rahmlow M, Shuster EA, Dominik J et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch. Neurol. 65(11), 1538–1539 (2008).
  • Warnatz K, Peter HH, Schumacher M et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann. Rheum. Dis. 62(1), 50–57 (2003).
  • Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63(2), 106–112 (2001).
  • Fukushima R, Kanamori S, Hirashiba M et al. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Toxicol. Sci. 108(2), 419–426 (2009).
  • Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann. Pharmacother. 35(11), 1485–1489 (2001).
  • Chambers CD, Johnson DL, Robinson LK et al.; Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 62(5), 1494–1503 (2010).
  • Kieseier B, Mednikova Z, Trabelsi N, Stüve O. Pregnancy outcomes from the teriflunomide treatment: retrospective analysis of a global pharmacovigilance database. Mult. Scler. 17, Abstract P472 (2011).
  • Confavreux C, Li DK, Freedman MS et al.; for the Teriflunomide Multiple Sclerosis Trial Group. Long-term follow-up of a Phase II study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult. Scler. 18(9), 1278–1289 (2012).
  • Li D, O’Connor P, Confavreux C, Byrnes WJ, Wang S, Traboulsee AL; Teriflunomide Multiple Sclerosis Trial Group. Long-term brain MRI and clinical assessments of teriflunomide for the treatment of multiple sclerosis: extension of a Phase II study. Mult. Scler. 16, S142 (2010).
  • Ebers GC, PRISMS (Prevention of Relapses and Disability by Interferon 𝛃-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon 𝛃-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498–1504 (1998).
  • Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268–1276 (1995).
  • The IFNB Multiple Sclerosis Study Group. Interferon b-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655–661 (1993).
  • Miller A, O’Connor P, Wolinsky J et al; Teriflunomide Multiple Sclerosis Trial Group. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a Phase III trial (TEMSO). Mult. Scler. 17, Abstract P438 (2011).
  • Comi G, O’Connor P, Wolinsky J et al; Teriflunomide Multiple Sclerosis Trial Group. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a Phase III trial (TEMSO). Mult. Scler. 17, Abstract P439 (2011).
  • O’Connor P, Wolinsky JS, Confavreux C et al.; Teriflunomide Multiple Sclerosis Trial Group. Extension of a Phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomisation. Mult. Scler. 17, Abstract P924 (2011).
  • Vermersch P, Czlonkowska A, Grimaldi L; TENERE Trial Group. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon b-1a in patients with relapsing multiple sclerosis. Presented at: 22nd Meeting of the European Neurological Society. Prague, Czech Republic, 9–12 June 2012.
  • Freedman MS, Wolinsky JS, Wamil B et al.; For the Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center. Teriflunomide added to interferon-ß in relapsing multiple sclerosis: a randomized Phase II trial. Neurology 78(23), 1877–1885 (2012).
  • Freedman M, Wolinsky JS, Frangin GA et al. Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Neurology 74, Abstract S21 001 (2010).
  • Gold R, Kappos L, Bar-Or A et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the Phase 3 DEFINE trial. Mult. Scler. 17, Abstract 95 (2011).
  • Kappos L, Radue EW, O’Connor P et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
  • Cohen JA, Barkhof F, Comi G et al.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402–415 (2010).
  • MacManus DG, Miller DH, Kappos L et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J. Neurol. 258(3), 449–456 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.